Haleos Labs Q3FY26 Revenue ₹947.83 Cr, Net Profit ₹66.49 Cr
Haleos Labs reported Q3FY26 consolidated results. Revenue from operations was ₹947.83 crore, up from ₹846.01 crore year-on-year. Net Profit After Tax was ₹66.49 crore, compared to ₹48.53 crore. For the nine months, revenue was ₹2,586.55 crore and PAT was ₹174.56 crore. EPS stood at ₹21.89.
The financial results show growth, which is generally positive for investors. However, the impact is considered medium as it reflects routine quarterly performance rather than a major strategic shift or event.
The company reported an increase in revenue and net profit for the quarter and nine months ended December 31, 2025, compared to the previous year, indicating positive financial performance.
Haleos Labs Limited (formerly SMS Lifesciences India Limited) announced its un-audited consolidated financial results for the quarter and nine months ended December 31, 2025. The company reported a Revenue from Operations of ₹9,478.31 lakh (₹947.83 crore) for the quarter ended December 31, 2025, an increase from ₹8,460.10 lakh (₹846.01 crore) in the same period last year. Net Profit After Tax (PAT) for the quarter stood at ₹664.89 lakh (₹66.49 crore), compared to ₹485.31 lakh (₹48.53 crore) in the corresponding quarter of the previous year. For the nine months ended December 31, 2025, Revenue from Operations was ₹25,865.54 lakh (₹2,586.55 crore), with a Net Profit After Tax of ₹1,745.63 lakh (₹174.56 crore). The company also reported Earnings Per Share (EPS) of ₹21.89 for the quarter. These results were recommended by the Audit Committee and approved by the Board of Directors on February 11, 2026, and have undergone a limited review by the statutory auditors.
What to do with a filing like this
HALEOS LABS LIMITED filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by HALEOS LABS LIMITED. Read the original for the full detail.